Abstract
Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists. The objective of this study was to assess the cost effectiveness of a HMGA2 prognostic test based on HMGA2+/HMGA2- expression, which improves genetic risk stratification in acute myeloid leukemia, and compare this test with the current standard of care in Canada. A cost-effectiveness model was developed from the Canadian National Healthcare Service and societal perspective using data from the Quebec Leukemia Cell Bank, published literature, and physician surveys. The model includes a lifetime horizon assessing the HMGA2 test vs. standard of care. The HMGA2 test outperformed the standard of care at all time horizons culminating with estimated improvements of 1.92 and 3.12 months in leukemia-free survival and overall survival, respectively. Costs associated with the HMGA2 test were consistently lower, except diagnostic costs, routine medical costs, and costs related to infections and false positives. From a societal perspective, total lifetime costs were $161,358 CAD and $151,908 CAD with the standard of care and the HMGA2 te...Continue Reading
References
Mar 29, 2001·Journal of Hematotherapy & Stem Cell Research·C A Uyl-de GrootB M van Ineveld
Mar 29, 2002·Bone Marrow Transplantation·L GopcsaK Paloczi
Jul 9, 2004·Cancer·Norbert VeyDominique Maraninchi
Oct 20, 2004·Cancer·Shelby D ReedKevin A Schulman
Mar 9, 2006·Blood·UNKNOWN Cancer and Leukemia Group B 8461Clara D Bloomfield
Apr 3, 2009·Journal of Cell Science·Asne Jul-LarsenStig Ove Bøe
Apr 14, 2010·Blood·David GrimwadeUNKNOWN National Cancer Research Institute Adult Leukaemia Working Group
Jul 16, 2010·Cancer·Jacob M RoweMartin S Tallman
May 21, 2011·Blood·Veronika RockovaPeter J M Valk
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterElihu H Estey
Sep 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Krzysztof MrózekClara D Bloomfield
Jan 24, 2013·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Nicholas R Latimer
Apr 22, 2016·British Journal of Haematology·Sonya CressmanStuart J Peacock
Nov 1, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·A LeunisC A Uyl-De Groot
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Aug 1, 2018·Blood Cancer Journal·Miriam MarquisJosée Hébert